Trulicity Cost in Utah 2026: Cash Price, Insurance, and Alternatives

What Does Trulicity Actually Cost in Utah in 2026?

The Eli Lilly list price for Trulicity sits at $931 per month in 2026, and that figure holds across Utah retail chains including Smith's, Harmons, Costco, and independent pharmacies. Without insurance or a manufacturer coupon, a patient filling a four-pen box of dulaglutide 1.5 mg faces roughly $11,172 per year out of pocket.

Price variation between zip codes in Utah is minimal because the list price is set by the manufacturer, not the pharmacy. What changes the number a patient actually pays is their insurance tier, whether they carry a savings card, or whether they access a compounding pharmacy.

How the List Price Compares Nationally

Dulaglutide's $931 Utah list price matches the national average Eli Lilly wholesale acquisition cost. That price is not discounted at the pharmacy counter unless a patient presents a valid insurance card or the Lilly Savings Card. Some GoodRx coupons bring the price to approximately $800 to $870 at select Utah retailers, but this still represents a substantial monthly burden for uninsured patients.

Where Prices Are Lowest in Utah

Costco Pharmacy in Salt Lake City and West Valley City consistently lists dulaglutide among the lower-priced retail options in the state, though the difference rarely exceeds $40 to $60 below the standard list price. Checking GoodRx, RxSaver, and NeedyMeds before each fill can surface short-term promotions, but none of these tools eliminate the underlying cost problem for cash-pay patients.

Does Utah Medicaid Cover Trulicity?

Utah Medicaid does not cover Trulicity (dulaglutide) for type 2 diabetes as of 2026. Patients enrolled in Utah's traditional Medicaid or the ACCESSHealth managed care plan will not have dulaglutide on the preferred drug list (PDL) and cannot obtain it through standard Medicaid billing.

This gap affects a meaningful share of Utah's low-income diabetic population. The Utah Department of Health and Human Services manages the Medicaid PDL, and GLP-1 receptor agonists as a class face inconsistent coverage across state Medicaid programs nationwide. A 2023 analysis in JAMA Network Open found that only 27 of 50 state Medicaid programs covered at least one GLP-1 agonist for diabetes on their PDL without prior authorization.

Prior Authorization and Exception Pathways

Even when a drug is not on the PDL, Utah Medicaid allows prescribers to submit a prior authorization (PA) request for non-preferred medications. Approval rates for off-PDL GLP-1 agents under Utah Medicaid are low without documentation of failure on first-line metformin and at least one sulfonylurea. A prescriber who can document cardiovascular risk or documented intolerance to formulary alternatives has a stronger PA case, given the REWIND trial data showing dulaglutide reduced major adverse cardiovascular events (MACE) by 12% relative to placebo over a median follow-up of 5.4 years in 9,901 patients with type 2 diabetes [1].

CHIP and Dual-Eligible Patients

Children on Utah CHIP and patients who are dual-eligible for Medicare and Medicaid face separate formulary rules. Medicare Part D plans do cover dulaglutide on various tiers, and dual-eligible patients should verify their specific Part D plan's tier placement before assuming no coverage exists.

Private Insurance Coverage for Trulicity in Utah

Most commercial insurance plans sold in Utah cover dulaglutide on Tier 3 or Tier 4, which typically means a copay of $60 to $150 per month after the deductible is met. The actual out-of-pocket cost depends heavily on whether the patient has met their deductible and which specific formulary tier their plan places dulaglutide on.

Major Payers in Utah

SelectHealth, the dominant Utah insurer tied to Intermountain Health, covers dulaglutide for type 2 diabetes with a PA requirement confirming a hemoglobin A1c of 7.5% or higher and a trial of metformin. Regence BlueCross BlueShield of Utah, PEHP (the state employee plan), and the major national carriers (Aetna, UnitedHealthcare, Cigna) all list dulaglutide on their Utah formularies as of 2026, though tier placement and step-therapy requirements differ by plan year.

PEHP, which covers Utah state government employees, places Trulicity on Tier 3 with a PA for diabetes. The monthly copay under PEHP's standard plan runs approximately $75 after deductible.

Checking Your Specific Plan

The single most reliable way to verify coverage is to call the member services number on the back of your insurance card and ask three specific questions: Is dulaglutide (NDC 00002-1434-06 for the 1.5 mg pen) covered on my formulary? What tier? Is prior authorization required? Getting those answers in writing via a benefits explanation letter protects against mid-year formulary changes.

The Eli Lilly Insulin Value Program and Trulicity Savings Card

Eli Lilly offers the Trulicity Savings Card through its website for commercially insured patients, reducing the monthly copay to as low as $25 per month for eligible individuals. The card is not usable by patients with government insurance including Medicare, Medicaid, TRICARE, or VA coverage, and is not valid in Utah if the patient's primary coverage is a government plan.

Eligibility Requirements

To use the Lilly Savings Card in Utah, a patient must: have a valid Trulicity prescription from a licensed Utah prescriber, be covered by commercial (private) insurance that covers Trulicity, and not be enrolled in any federal or state healthcare program for that prescription. The card can be activated online at LillyInsulinValueProgram.com or by calling 1-800-545-5979.

Lilly Cares Foundation for Uninsured Patients

Uninsured patients who do not qualify for the savings card may apply to the Lilly Cares Foundation Patient Assistance Program, which provides Trulicity at no cost to patients meeting income thresholds. Applications require documentation of income below 400% of the federal poverty level and proof of no insurance coverage for the medication.

Is Compounded Dulaglutide Legal in Utah?

Compounded dulaglutide is available through state-licensed 503A compounding pharmacies in Utah. However, legality at the federal level involves ongoing regulatory nuance that patients and prescribers must understand before pursuing this route.

FDA Status of Compounded GLP-1 Drugs

The FDA placed semaglutide on the drug shortage list in 2022, which opened a legal pathway for 503A and 503B compounders to produce compounded semaglutide. Dulaglutide has not been formally added to the FDA shortage list in the same manner, but 503A pharmacies (which compound for individual patient prescriptions) operate under a different legal framework than 503B outsourcing facilities. The FDA's guidance on compounding under 503A of the Federal Food, Drug, and Cosmetic Act allows a licensed pharmacist to compound a drug that is not on the FDA-approved list for commercial manufacture, provided a licensed prescriber submits a valid patient-specific prescription.

What Utah State Law Says

Utah follows federal 503A standards and does not impose additional restrictions beyond federal law for compounding pharmacies. A licensed Utah compounding pharmacy with a 503A designation may compound dulaglutide for an individual patient given a valid prescription. The patient and prescriber both carry responsibility for ensuring the compounding pharmacy holds a current Utah Board of Pharmacy license.

Safety Considerations for Compounded Dulaglutide

Compounded products are not FDA-approved and have not undergone the same manufacturing quality controls as the branded product. A prescriber recommending compounded dulaglutide should verify the compounding pharmacy's accreditation with the Pharmacy Compounding Accreditation Board (PCAB). The American Diabetes Association's 2024 Standards of Care state: "Compounded GLP-1 receptor agonist products are not FDA-approved and their safety, efficacy, and quality cannot be assured; their use should be approached with caution." [2]

The HealthRX clinical team uses the following decision framework for Utah patients asking about compounded dulaglutide:

1. Confirm the patient has a documented indication (type 2 diabetes or obesity with BMI <27 plus one comorbidity).
2. Verify the compounding pharmacy holds a current Utah 503A license and PCAB accreditation.
3. Obtain baseline metabolic panel, HbA1c, and thyroid history before initiating.
4. Set a 12-week reassessment: if HbA1c has not improved by at least 0.5% or weight has not decreased by at least 3%, reconsider the formulation source or dose.
5. Document the patient's informed consent noting the non-FDA-approved status of the compounded product.

Why Trulicity Is Prescribed: Clinical Evidence Summary

Dulaglutide is a once-weekly GLP-1 receptor agonist approved by the FDA in 2014 for glycemic control in adults with type 2 diabetes. The FDA prescribing information lists the approved adult doses as 0.75 mg once weekly (starting dose) and 1.5 mg once weekly (maintenance), with 3.0 mg and 4.5 mg available for additional glycemic control.

REWIND Trial: Cardiovascular Outcomes

The REWIND trial (NCT01394952, N=9,901) randomized patients with type 2 diabetes and either established cardiovascular disease or cardiovascular risk factors to dulaglutide 1.5 mg weekly versus placebo for a median of 5.4 years. The primary composite endpoint of MACE (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) occurred in 12.0% of the dulaglutide group versus 13.4% in the placebo group, a hazard ratio of 0.88 (95% CI 0.79 to 0.99; P<0.026) [1]. This made REWIND the first GLP-1 trial to show CV benefit in a predominantly primary-prevention population.

Glycemic and Weight Outcomes

In the AWARD-5 trial (N=1,098), dulaglutide 1.5 mg produced a mean HbA1c reduction of 1.51% from baseline at 52 weeks compared with 1.30% for sitagliptin 100 mg (P<0.001). Body weight decreased by 3.03 kg in the dulaglutide arm versus 1.37 kg in the sitagliptin arm. Dulaglutide is not FDA-approved for weight loss as a standalone indication, unlike semaglutide 2.4 mg (Wegovy).

How It Compares to Semaglutide in Utah

Both dulaglutide and semaglutide (Ozempic, Wegovy) are available in Utah at similar list prices. Semaglutide 1 mg (Ozempic) carries a list price of approximately $936/month in 2026. For patients whose primary goal is cardiovascular protection alongside glycemic control, REWIND-level evidence supports dulaglutide as a cost-comparable option. For patients prioritizing weight loss, the STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo, a result dulaglutide does not match at any approved dose. [3]

Getting Trulicity via Telehealth in Utah

Telehealth prescribing of Trulicity is fully legal in Utah as of 2026. Utah passed the Utah Telehealth Act (Utah Code Title 26B) and participates in the Interstate Medical Licensure Compact, allowing out-of-state physicians licensed through the compact to prescribe to Utah patients via synchronous video visits.

What a Telehealth Visit Requires

A prescriber must establish a valid patient-physician relationship before writing a controlled or non-controlled prescription, even via telehealth. For dulaglutide, this means a synchronous video or audio-video visit where the prescriber reviews current medications, recent HbA1c, renal function (eGFR <15 mL/min/1.73m2 is not a formal contraindication but warrants caution), personal or family history of medullary thyroid carcinoma, and MEN2 syndrome history. A prescription generated through a questionnaire-only visit without a live encounter does not meet Utah's telehealth prescribing standards.

HealthRX Utah Telehealth Workflow

HealthRX connects Utah patients with board-certified endocrinologists and internal medicine physicians licensed in Utah. A patient with a documented type 2 diabetes diagnosis, a recent HbA1c above 7.0%, and no contraindications can typically receive a Trulicity prescription within 48 hours of a completed telehealth visit. The HealthRX clinical team also reviews insurance prior authorization requirements and assists with Lilly Savings Card enrollment during the intake process.

Strategies to Lower Trulicity Cost in Utah: A Ranked Summary

Patients in Utah have several concrete paths to reduce the $931 monthly list price, ordered here from highest to lowest expected savings.

Option 1: Lilly Savings Card (Commercially Insured)

For patients with commercial insurance covering Trulicity, the savings card brings the copay to $25/month. This is the highest-value option for employed Utahns with employer-sponsored insurance.

Option 2: Lilly Cares Foundation (Uninsured, Low Income)

Uninsured patients below 400% FPL may receive Trulicity at no cost through Lilly Cares. The application turnaround time averages 4 to 6 weeks from submission.

Option 3: Compounded Dulaglutide via 503A Pharmacy

A licensed Utah 503A compounding pharmacy may provide dulaglutide at significantly lower cost than the branded product. Price will vary by pharmacy and dose; patients should request an itemized quote and confirm PCAB accreditation before proceeding.

Option 4: GoodRx or RxSaver Coupons

GoodRx coupons at Costco or Walmart pharmacies in Salt Lake County have brought the cash price to approximately $810 to $860 in early 2026. This is a partial reduction, not elimination, of the list price burden.

Option 5: Switching to a Formulary-Preferred GLP-1

Some Utah insurance plans prefer exenatide extended-release (Bydureon BCise) or liraglutide (Victoza) over dulaglutide at lower cost-sharing tiers. A prescriber can submit a therapeutic substitution request if the evidence supports the alternative for that patient's specific comorbidity profile.

Initiating and Dosing Dulaglutide in Utah: Clinical Basics

Trulicity is injected subcutaneously once weekly at any time of day, with or without food. The starting dose of 0.75 mg per week may be increased to 1.5 mg after at least four weeks if additional glycemic control is needed. Further increases to 3.0 mg and 4.5 mg are available in 4-week increments.

Injection sites include the abdomen, thigh, or upper arm. The prefilled single-dose pen does not require refrigeration for up to 14 days at room temperature below 86°F (30°C). Utah's summer temperatures in areas like St. George and Moab regularly exceed 100°F, so patients traveling outdoors should carry an insulated medication pouch.

The most common adverse effects are nausea (12.4% at 0.75 mg, 21.1% at 1.5 mg in AWARD-5), diarrhea, and vomiting, all of which typically resolve within the first 4 to 8 weeks of therapy. The FDA prescribing label carries a boxed warning for thyroid C-cell tumors based on rodent studies; dulaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.